(Adnkronos) - "Abbiamo ancora 44 mila casi di nuovi tumori al polmone all’anno, crescono in donne e giovani. Ma l’incidenza dei farmaci innovativi, come quelli a bersaglio molecolare e l’immunoterapia aumentano di tanto le aspettative e la qualità di vita dei pazienti. Ed è indispensabile l’evoluzione del Fondo per i farmaci innovativi, lo strumento corretto per mettere a terra tutte le terapie in grado di sostenere la battaglia al tumore del polmone”. Lo ha detto Silvia Novello, responsabile Oncologia medica all’Ospedale San Luigi Gonzaga di Orbassano, ordinario di Oncologia medica all’Università degli Studi di Torino e presidente Walce (Women Against Lung Cancer in Europe) partecipano al Convegno ‘ ‘Inventing for lung. Il contributo dell’innovazione per il trattamento del tumore al polmone’, promosso da Msd Italia.
Category
🗞
NewsTranscript
00:00The lung tumor can unfortunately still be framed as one of the big killers on the national territory.
00:11We still record 44,000 new cases a year and there are some worrying facts.
00:20The first worrying fact is certainly the fact that this tumor still has a close link with cigarette smoke.
00:27The fact that 85% of our patients have been strong smokers
00:33means that if we were magically able to eliminate cigarette smoke,
00:37the lung tumor would suddenly become a rare pathology.
00:41The other worrying fact is the increase among the female population
00:45compared to the male population, which sees a condition of stability in the number of new cases.
00:52The number of new cases among women and the mortality rate is definitely increasing.
00:58And then there are the young people who get sick.
01:01Despite the fact that the average age for the lung tumor continues to be around 69 years old,
01:08there is no doubt that this pathology is increasing even in much younger subjects.
01:13Innovative treatments for the lung tumor are having a significant impact.
01:19They are doing it in terms of quantity of life gained, but above all in terms of quality of life gained.
01:27The introduction of molecular-target drugs and the introduction of immunotherapy
01:33have radically changed our treatment algorithm,
01:38which means that patients who receive these treatments have a discreet quality of life
01:45and have a much longer life expectancy compared to what we could achieve with only chemotherapy.
01:51The development of drugs and the funding of innovative drugs is fundamental,
01:57in the sense that all this innovation does not touch the ground, does not find ground.
02:02If these funds are not allocated, I would say in useful quantities and times, so it is fundamental.
02:11We cannot think that these patients live only thanks to clinical studies,
02:17which is true, they represent a bridge between the unavailability of the drug and its commercial entry.
02:24But then you have to offer the next step.
02:27Until a few years ago, we could not talk about secondary prevention,
02:32that is, we could not talk about screening for the lung tumor,
02:35as is done for other solid tumors, such as the cervical tumor or the breast tumor.
02:40Instead, finally, for about a year and a half, a ministerial network is activated,
02:45which is the RISP network, which sees 18 centers open on the national territory,
02:51in which smokers or ex-smokers aged between 55 and 75 years of age
02:59receive a spiral attack, which is shown to be an examination able to reduce mortality for this pathology,
03:06but they receive it only for a primary prevention.
03:10So, for the first time, secondary prevention and everything that is counseling against smoking
03:16travel together in a prevention program.